ID   SG568
AC   CVCL_A1ZU
DR   IARC_TP53; 7402
DR   Wikidata; Q105511038
RX   PubMed=8402660;
RX   PubMed=9563901;
CC   Virology: EBV-negative.
CC   Doubling time: 23 hours (PubMed=8402660).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.522_523ins3; Zygosity=Unspecified (PubMed=8402660).
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 10-04-25; Version: 6
//
RX   PubMed=8402660;
RA   O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T.,
RA   Kohn K.W.;
RT   "Role of the p53 tumor suppressor gene in cell cycle arrest and
RT   radiosensitivity of Burkitt's lymphoma cell lines.";
RL   Cancer Res. 53:4776-4780(1993).
//
RX   PubMed=9563901;
RA   Fan S.-J., Cherney B.W., Reinhold W.C., Rucker K., O'Connor P.M.;
RT   "Disruption of p53 function in immortalized human cells does not
RT   affect survival or apoptosis after taxol or vincristine treatment.";
RL   Clin. Cancer Res. 4:1047-1054(1998).
//